Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun;24(2):524-531.
doi: 10.1038/s41391-020-00309-w. Epub 2021 Jan 26.

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide

M Del Re #  1 , V Conteduca #  2 , S Crucitta  1 , G Gurioli  2 , C Casadei  2 , G Restante  1 , G Schepisi  2 , C Lolli  2 , F Cucchiara  1 , R Danesi  3 , U De Giorgi  2
Affiliations

Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide

M Del Re et al. Prostate Cancer Prostatic Dis. 2021 Jun.

Abstract

Background: Androgen receptor (AR) signaling inhibitors represent the standard treatment in metastatic castration resistance prostate cancer (mCRPC) patients. However, some patients display a primary resistance, and several studies investigated the role of the AR as a predictive biomarker of response to treatment. This study is aimed to evaluate the role of AR in liquid biopsy to predict clinical outcome to AR signaling inhibitors in mCRPC patients.

Methods: Six milliliters of plasma samples were collected before first-line treatment with abiraterone or enzalutamide. Circulating free DNA (cfDNA) and exosome-RNA were isolated for analysis of AR gain and AR splice variant 7 (AR-V7), respectively, by digital droplet PCR.

Results: Eighty-four mCRPC patients received abiraterone (n = 40) or enzalutamide (n = 44) as first-line therapy. Twelve patients (14.3%) presented AR gain and 30 (35.7%) AR-V7+ at baseline. Median progression-free survival (PFS) and overall survival (OS) were significantly longer in AR-V7- vs AR-V7+ patients (24.3 vs 5.4 months, p < 0.0001; not reached vs 16.2 months, p = 0.0001, respectively). Patients carrying the AR gain had a median PFS of 4.8 vs 24.3 months for AR normal patients (p < 0.0001). Median OS was significantly longer in AR normal vs patients with AR gain (not reached vs 8.17 months, p < 0.0001). A significant correlation between AR-V7 and AR gain was observed (r = 0.28; p = 0.01). The AR gain/AR-V7 combined analysis confirmed a strong predictive effect for biomarkers combination vs patients without any AR aberration (PFS 3.8 vs 28 month, respectively; OS 6.1 vs not reached, respectively; p < 0.0001).

Conclusions: The present study demonstrates that cfDNA and exosome-RNA are both a reliable source of AR variants and their combined detection in liquid biopsy predicts resistance to AR signaling inhibitors.

PubMed Disclaimer

Conflict of interest statement

MDR received speaker honoraria from Astellas, Astra Zeneca, Celgene, Novartis, Pfizer, Bio-Rad Janssen-Cilag, Sanofi-Aventis; consulting fee from Ipsen and Janssen-Cilag; Speaker’s bureau: Celgene, Janssen, Sanofi; travel support from Janssen, Bio-Rad. VC has received speaker honoraria or travel support from Astellas, Janssen-Cilag, and Sanofi-Aventis, and has received consulting fee from Bayer. RD received honoraria for scientific advisory board and consulting relationship from Ipsen, Novartis, Pfizer, Sanofi Genzyme, AstraZeneca, Janssen, Gilead, Lilly, Gilead, EUSA Pharma; travel support from Ipsen, Sanofi Genzyme. UDG received honoraria as consulting or advisory role for Pfizer, Janssen, Astellas Pharma, Sanofi, Bristol-Myers Squibb, Bayer, Ipsen, Merck; received institutional research funding from Sanofi, AstraZeneca, Roche; received travel support from Bristol-Myers Squibb, Ipsen, Janssen, Pfizer. All remaining authors have declared no conflicts of interest.

Figures

Fig. 1
Fig. 1. Kaplan–Meier curves.
Progression free survival (PFS, A) and overall survival (OS, B) according to AR-gain status in the overall population.
Fig. 2
Fig. 2. Kaplan–Meier curves.
Progression free survival (PFS, A) and overall survival (OS, B) according to AR-V7 status in the overall population.
Fig. 3
Fig. 3
The linear correlation between AR-gain and AR-V7.
Fig. 4
Fig. 4. Kaplan–Meier curves.
Progression free survival (PFS, A) and Overall Survival (OS, B) according to AR-gain and AR-V7 combined status in the overall population.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34. doi: 10.3322/caac.21551. - DOI - PubMed
    1. Davies A, Conteduca V, Zoubeidi A, Beltran H. Biological evolution of castration-resistant prostate cancer. Eur Urol Focus. 2019;5:147–54. doi: 10.1016/j.euf.2019.01.016. - DOI - PubMed
    1. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med. 2004;10:33–9. doi: 10.1038/nm972. - DOI - PubMed
    1. Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371:424–33. doi: 10.1056/NEJMoa1405095. - DOI - PMC - PubMed
    1. Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187–97. doi: 10.1056/NEJMoa1207506. - DOI - PubMed

MeSH terms